Prof. Paolo Ghia discusses the latest 7-year follow-up IMBRUVICA® data in 1L CLL
RESONATE-2 reinforces confidence in long-term survival with IMBRUVICA®, including those with high-risk genetic features
Ghia P, et al. Up to 7 years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Poster presented at: 26th congress of EHA; 9–12 June 2021; virtual meeting.